Skip to Content

Charles River Laboratories International Inc CRL Stock Quote

| Rating as of

Morningstar‘s Stock Analysis CRL

Valuation
Currency in USD
Is it the right time to buy or sell?
Is it the right time to buy or sell?

1-Star Price

INVESTOR

5-Star Price

INVESTOR

Economic Moat

INVESTOR

Capital Allocation

INVESTOR

Charles River Reports Strong Outlook for 2022; Lifting FVE to $260

Rachel Elfman Equity Analyst

Business Strategy and Outlook

| Rachel Elfman |

Animal research models have been the foundation of Charles River's business since 1947, and the company has expanded to provide solutions encompassing research models and related services, drug discovery, preclinical testing, and manufacturing support. It services nearly all top and mid-tier biopharma players.

Unlock Our Full Analysis With Morningstar Investor

Key Statistics CRL

Company Profile CRL

Business Description

Charles River Laboratories was founded in 1947 and is a leading provider of drug discovery and development services. The company’s research model & services segment is the leading provider of animal models for laboratory testing, which breeds and delivers animal research models with specific genetic characteristics for preclinical studies around the world. The discovery & safety assessment segment includes services required to take a drug through the early development process, including discovery services. The manufacturing support segment includes microbial solutions, which provides in vitro (non-animal) testing products, biologics testing services, and avian vaccine services.

Contact
251 Ballardvale Street
Wilmington, MA, 01887
T +1 781 222-6000
Industry Diagnostics & Research
Most Recent Earnings Jun 30, 2022
Fiscal Year End Dec 31, 2022
Stock Type Aggressive Growth
Employees 20,000

Related News CRL